VALBIOTIS SA (ALVAL.PA) Stock Fundamental Analysis

Europe • Euronext Paris • EPA:ALVAL • FR0013254851

1.094 EUR
-0.04 (-3.19%)
Last: Feb 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ALVAL. ALVAL was compared to 81 industry peers in the Biotechnology industry. While ALVAL seems to be doing ok healthwise, there are quite some concerns on its profitability. ALVAL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ALVAL has reported negative net income.
  • In the past year ALVAL has reported a negative cash flow from operations.
  • ALVAL had negative earnings in each of the past 5 years.
  • ALVAL had negative operating cash flow in 4 of the past 5 years.
ALVAL.PA Yearly Net Income VS EBIT VS OCF VS FCFALVAL.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M

1.2 Ratios

  • ALVAL has a worse Return On Assets (-55.87%) than 67.90% of its industry peers.
  • The Return On Equity of ALVAL (-94.60%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -55.87%
ROE -94.6%
ROIC N/A
ROA(3y)-39.5%
ROA(5y)-33.42%
ROE(3y)-75.49%
ROE(5y)-68.14%
ROIC(3y)N/A
ROIC(5y)N/A
ALVAL.PA Yearly ROA, ROE, ROICALVAL.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ALVAL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALVAL.PA Yearly Profit, Operating, Gross MarginsALVAL.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • ALVAL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ALVAL remains at a similar level compared to 1 year ago.
  • ALVAL has more shares outstanding than it did 5 years ago.
  • ALVAL has a worse debt/assets ratio than last year.
ALVAL.PA Yearly Shares OutstandingALVAL.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ALVAL.PA Yearly Total Debt VS Total AssetsALVAL.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • ALVAL has an Altman-Z score of 1.34. This is a bad value and indicates that ALVAL is not financially healthy and even has some risk of bankruptcy.
  • ALVAL's Altman-Z score of 1.34 is fine compared to the rest of the industry. ALVAL outperforms 62.96% of its industry peers.
  • ALVAL has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of ALVAL (0.25) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 1.34
ROIC/WACCN/A
WACC7.32%
ALVAL.PA Yearly LT Debt VS Equity VS FCFALVAL.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

  • ALVAL has a Current Ratio of 3.43. This indicates that ALVAL is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 3.43, ALVAL is doing good in the industry, outperforming 66.67% of the companies in the same industry.
  • A Quick Ratio of 2.93 indicates that ALVAL has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.93, ALVAL is in the better half of the industry, outperforming 62.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.43
Quick Ratio 2.93
ALVAL.PA Yearly Current Assets VS Current LiabilitesALVAL.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • ALVAL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.52%.
  • The Revenue for ALVAL has decreased by -10.44% in the past year. This is quite bad
  • Measured over the past years, ALVAL shows a quite strong growth in Revenue. The Revenue has been growing by 13.97% on average per year.
EPS 1Y (TTM)-7.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.13%
Revenue 1Y (TTM)-10.44%
Revenue growth 3Y-16.26%
Revenue growth 5Y13.97%
Sales Q2Q%848.57%

3.2 Future

  • The Earnings Per Share is expected to grow by 25.24% on average over the next years. This is a very strong growth
  • ALVAL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 343.53% yearly.
EPS Next Y33.86%
EPS Next 2Y25.75%
EPS Next 3Y25.24%
EPS Next 5YN/A
Revenue Next Year375%
Revenue Next 2Y461.25%
Revenue Next 3Y343.53%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALVAL.PA Yearly Revenue VS EstimatesALVAL.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M
ALVAL.PA Yearly EPS VS EstimatesALVAL.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • ALVAL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALVAL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALVAL.PA Price Earnings VS Forward Price EarningsALVAL.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALVAL.PA Per share dataALVAL.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ALVAL's earnings are expected to grow with 25.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.75%
EPS Next 3Y25.24%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ALVAL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VALBIOTIS SA

EPA:ALVAL (2/6/2026, 7:00:00 PM)

1.094

-0.04 (-3.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-27
Earnings (Next)03-02
Inst Owners2.31%
Inst Owner ChangeN/A
Ins Owners2.99%
Ins Owner ChangeN/A
Market Cap25.93M
Revenue(TTM)472.00K
Net Income(TTM)-11.12M
Analysts85.45
Price Target2.18 (99.27%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.54%
PT rev (3m)-1.54%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-20.87%
EPS NY rev (3m)-21.93%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 54.93
P/FCF N/A
P/OCF N/A
P/B 2.21
P/tB 2.44
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS0.02
BVpS0.5
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -55.87%
ROE -94.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.5%
ROA(5y)-33.42%
ROE(3y)-75.49%
ROE(5y)-68.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -263.54%
Cap/Sales 53.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.43
Quick Ratio 2.93
Altman-Z 1.34
F-Score3
WACC7.32%
ROIC/WACCN/A
Cap/Depr(3y)37.28%
Cap/Depr(5y)37.7%
Cap/Sales(3y)63.68%
Cap/Sales(5y)68.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.13%
EPS Next Y33.86%
EPS Next 2Y25.75%
EPS Next 3Y25.24%
EPS Next 5YN/A
Revenue 1Y (TTM)-10.44%
Revenue growth 3Y-16.26%
Revenue growth 5Y13.97%
Sales Q2Q%848.57%
Revenue Next Year375%
Revenue Next 2Y461.25%
Revenue Next 3Y343.53%
Revenue Next 5YN/A
EBIT growth 1Y-25.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.81%
EBIT Next 3Y25.32%
EBIT Next 5Y25.3%
FCF growth 1Y0.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.27%
OCF growth 3YN/A
OCF growth 5YN/A

VALBIOTIS SA / ALVAL.PA FAQ

What is the fundamental rating for ALVAL stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALVAL.PA.


Can you provide the valuation status for VALBIOTIS SA?

ChartMill assigns a valuation rating of 1 / 10 to VALBIOTIS SA (ALVAL.PA). This can be considered as Overvalued.


What is the profitability of ALVAL stock?

VALBIOTIS SA (ALVAL.PA) has a profitability rating of 0 / 10.


How financially healthy is VALBIOTIS SA?

The financial health rating of VALBIOTIS SA (ALVAL.PA) is 4 / 10.


Can you provide the expected EPS growth for ALVAL stock?

The Earnings per Share (EPS) of VALBIOTIS SA (ALVAL.PA) is expected to grow by 33.86% in the next year.